ASH 2020 | Predicting IMiD response in multiple myeloma patients
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses the possible mechanisms behind IMiD response in multiple myeloma patients. Plasma cells have a set anti-oxidative stress capacity, modulated by the thyroxine pathway, which clears peroxide. IMiDs inhibit that pathway and, as a result, treated cells might be more susceptible to the toxic effects of peroxide. While this area needs to be further investigated, it may have the potential to predict patient responses to IMiD treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Rafael Fonseca, MD, has done consultancy work with Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Karyopharm, Merck, Juno, Kite, Aduro, OncoTracker, Oncopeptides, GSK and AbbVie; and has participated in scientific advisory boards for Adaptive Biotechnologies, Caris Life Sciences and OncoTracker.
